Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study

Acta Oncologica

Volumn 54, Issue 4, 2015, Pages 543-549

  Lundgren, Claudia ^a,e   Ahlin, Cecilia ^c   Holmberg, Lars ^b   Amini, Rose Marie ^a   Fjällskog, Marie Louise ^a   Blomqvist, Carl ^a,d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Regional Cancer Centre Uppsala Orebro   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e Section of Radiology   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B; CYCLIN E; CYCLIN E1; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER; UNCLASSIFIED DRUG; CCNE1 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRADIATION; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR VOLUME; ANALYSIS OF VARIANCE; BREAST TUMOR; CASE CONTROL STUDY; LYMPH NODE; METABOLISM; MORTALITY; ODDS RATIO; PATHOLOGY; PROGNOSIS;

AGED; ANALYSIS OF VARIANCE; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYCLIN A; CYCLIN B; CYCLIN E; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPH NODES; ODDS RATIO; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR BURDEN;

EID: 84925384765     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.965274     Document Type: Article

References (25)

1. Tryggvadottir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm HH, et al. Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 624-31.
2. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207-19.
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-29.
4. Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, et al. Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2501-6.
5. Nimeus-Malmstrom E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, Amini RM, et al. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer 2010; 127: 961-7.
6. Weinberg RA. pRb and control of the cell cycle clock. In: The biology of cancer, 1st ed. London; Garland Science: 2006. p 255-306.
7. Wang L, Shao ZM. Cyclin e expression and prognosis in breast cancer patients: A meta-analysis of published studies. Cancer Invest 2006; 24: 581-7.
8. Bostrom P, Soderstrom M, Palokangas T, Vahlberg T, Collan Y, Carpen O, et al. Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors. BMC Res Notes 2009; 2: 140.
9. Nielsen NH, Arnerlov C, Emdin SO, Landberg G. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer 1996; 74: 874-80.
10. Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, et al. p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst 2006; 98: 1723-31.
11. Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol 2005; 16: 735-42.
12. Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Begin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 2004; 64: 830-5.
13. Aaltonen K, Blomqvist C, Amini RM, Eerola H, Aittomaki K, Heikkila P, et al. Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res 2008; 14: 1976-83.
14. Ahlin C, Gruhne B, Holmqvist M, Zetterberg A, Fjallskog ML. Aberrant expression of cyclin E in low-risk node negative breast cancer. Acta Oncol 2008; 47: 1539-45.
15. Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 2006;12: 3319-28.
16. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347: 1566-75.
17. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001; 93: 283-7.
18. Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004; 25: 375-80.
19. Rudolph P, Kuhling H, Alm P, Ferno M, Baldetorp B, Olsson H, et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int J Cancer 2003; 105: 674-80.
20. Kuhling H, Alm P, Olsson H, Ferno M, Baldetorp B, Parwaresch R, et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J Pathol 2003; 199: 424-31.
21. Poikonen P, Sjöström J, Amini RM, Villman K, Ahlgren J, Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005; 93: 515-9.
22. Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 2011; 11: 486.
23. O'Shaughnessy J, Brownstein C, Horsch S, Scotto N, Oncology US. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): Efficacy results. Breast 2011; 20: S65.
24. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008; 10: R65.
25. Geradts J, Bean SM, Bentley RC, Barry WT The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features. Cancer Invest 2010; 28: 969-77.